Basking Biosciences
Basking Biosciences: A startup developing therapies to restore brain blood flow and prevent stroke damage.
- 7
- Private company
- Cary, NC, USUnited States
Basking Biosciences: A startup developing therapies to restore brain blood flow and prevent stroke damage.
baskingbiosciences.comCrawled Oct 15, 2026
Developing targeted, reversible therapies with unique on-off switch mechanisms for acute thrombotic conditions. Safer, more precise clot intervention.
Advancing reversible therapies targeting von Willebrand Factor for safer treatment of acute thrombotic conditions. Precision control when seconds matter.
Basking Biosciences reports positive topline results from a phase-one trial of **BB-025**, a rapid-acting reversal agent targeting its lead candidate **BB-031**. BB-031 is an RNA aptamer designed to inhibit von Willebrand factor (vWF) and improve blood flow in acute ischemic conditions. The study demonstrates BB-025’s ability to neutralize BB-031 within minutes, addressing a critical need for controlled reversal in therapeutic applications.
Sep 2026NeuroNews InternationalNews article
Basking Biosciences reports positive topline Phase 1 results for **BB-025**, its reversal agent for **BB-031**, an experimental thrombolytic therapy targeting acute ischemic stroke. BB-025 rapidly neutralizes BB-031 by binding to and inhibiting its activity within minutes. The therapy aims to selectively block von Willebrand Factor (vWF), a key protein in clot formation, offering a targeted approach to stroke treatment.
Aug 2026Yahoo FinanceNews article
Basking Biosciences enrolls the first participants in a Phase 1 trial of **BB-025**, a drug designed to rapidly and selectively reverse the effects of its experimental stroke therapy **BB-031**. The study marks the first clinical evaluation of BB-025, supporting the company’s effort to develop a new approach to treating blood clots (thrombosis).
Nov 2025BioSpaceNews article
Basking Biosciences presents early clinical data on its reversible thrombolytic agent designed to treat ischemic stroke. The study evaluates safety and dose escalation in human trials, marking progress in developing a potential alternative to existing thrombolytic therapies. The therapy aims to dissolve blood clots while minimizing risks associated with current treatments.
Feb 2023Endovascular TodayNews article